TUCSON, Ariz.--(BUSINESS WIRE)--Calimmune Inc., a clinical-stage gene therapy company, has expanded its leadership team with the appointment of Tana Session as vice president, human resources. In addition, Jeffrey Bartlett, Ph.D., has been promoted to chief scientific officer to lead global research and development programs for Calimmune. Dr. Bartlett joined the company in 2012 as vice president, research and development.
“Tana and Jeff will each play significant roles in propelling Calimmune into its next phase of growth and clinical development,” said Louis Breton, chief executive officer of Calimmune. “Their contributions to the executive leadership team will provide further momentum for Calimmune as we near completion of our U.S. Phase I/II trial dosing of Cal-1 for the treatment of HIV/AIDS, and as we pursue new hematologic disease indications."
Ms. Session leads all recruiting, hiring, onboarding and training of Calimmune employees worldwide. She previously served in several executive positions in human resources for diverse New York- and California-based public and private institutions, including Golden State Water Company, Capco, Inc., The Center for Discovery, and Coleman Research Group. Additionally, Ms. Session founded and served as principal consultant for TMS Business Solutions Inc., a human resources consulting and coaching organization. Ms. Session earned her bachelor’s degree in business administration and her MBA with a concentration in organizational psychology and development. She holds certifications as Certified Career and Life Coach, Professional in Human Resources (PHR), Global Professional in Human Resources (GPHR), and SHRM Senior Certified Professional (SHRM-SCP).
Dr. Bartlett brings more than 20 years of experience in development of viral vectors, novel gene and cell-based therapies, and the transition of scientific innovation and early phase clinical studies into accepted treatments. As chief scientific officer, he oversees external and internal research programs, manufacturing, and clinical laboratory activities. He also provides scientific guidance for ongoing clinical programs and overall corporate strategy. Prior to Calimmune, Dr. Bartlett was an investigator within the Centers for Gene Therapy and Childhood Cancer at The Research Institute at Nationwide Children’s Hospital, and served as a tenured academic faculty member at The Ohio State University and the University of North Carolina at Chapel Hill. He was also the scientific founder of Nexigen Biologics and has served on numerous special emphasis and regular grant review panels for the National Institutes of Health, as well as on FDA and NIH advisory committees, including two terms on the NIH Recombinant DNA Advisory Committee. He is an inventor on numerous patents, patent applications and licensed technologies relating to viral vectors and cell and gene therapy. Dr. Bartlett holds a bachelor’s degree from Middlebury College in Vermont and a doctorate in molecular biology from the University of Pittsburgh School of Medicine.
Calimmune Inc. is a clinical-stage, international biotechnology company focused on developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune system. The company was founded in 2006 from technology developed in the labs of Nobel Laureate David Baltimore, Ph.D. (California Institute of Technology), Irvin Chen, Ph.D. (University of California, Los Angeles), and Inder M. Verma, Ph.D. (Salk Institute for Biological Studies). Calimmune’s lead product candidate for HIV, now in Phase I/II studies, is being evaluated as a one-time treatment to prevent HIV progression to AIDS. The company is headquartered in Tucson, Arizona, with labs and branch offices in Pasadena, California, and Sydney, Australia.